Navigation Links
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Date:6/15/2010

FREISING-WEIHENSTEPHAN, Germany, June 15, 2010 /PRNewswire/ -- Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and patients from the first cohort have been dosed.

"Meeting our goal of initiating this trial in the first half of 2010 demonstrates Pieris' commitment to establishing the safety and the therapeutic relevance of the Anticalin drug class," stated Stephen Yoder, CEO of Pieris. "Further, the high potency observed in preclinical studies, together with the small size and the lack of an antibody Fc domain, show promise of an attractive combined efficacy and safety profile for PRS-050."

The trial is designed to test PRS-050 in approximately 40 patients, who will receive the compound and then be monitored for safety and tolerability. The patients recruited for the trial are cancer patients with advanced, recurrent or metastatic solid tumors, refractory to standard therapy.

PRS-050 is an anti-VEGF (Vascular Endothelial Growth Factor) Anticalin discovered and developed internally at the company from Pieris' proprietary Anticalin libraries. PRS-050's mechanism of action is based on its ability to bind the VEGF ligand, thereby inhibiting tumor growth. VEGF's role in cancer angiogenesis, the mechanism by which cancer tumors increase blood vessel development to deliver key nutrients and oxygen is well established, both scientifically and clinically.

About Pieris


'/>"/>
SOURCE Pieris AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
2. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
3. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
4. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
5. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 WriteResult, LLC – a premier ... again shown superiority when it comes to meeting the ... ePRO portion of their most recent study closeout on-time ... chose WriteResult’s digital writing platform to collect Patient Reported ... to complete drew data from a number of assessments ...
(Date:8/26/2014)... and Bellingham, WA (PRWEB) August 26, 2014 ... engineering, visions for next-generation wearable technology, and inspiration ... numerous highlights at this year’s brighter, busier ... Diego, California, Convention Center. More than 4,400 international ... attended conferences, courses, an exhibition, and industry sessions ...
(Date:8/26/2014)... A new argument has just been added to ... its pedestal as the next big thing in ... as MX2 materials. An international collaboration of researchers ... of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... ultrafast charge transfer in photo-excited MX2 materials. The ...
(Date:8/26/2014)... ARBOR, Mich. , Aug. 26, 2014 /PRNewswire/ ... the development of breakthrough oral medicines to treat ... of immune modulation, today announced the appointment of ... the company,s scientific advisory board.  Dr. Singh will ... insight to advance Lycera,s multiple ongoing research programs ...
Breaking Biology Technology:A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4Competition for graphene 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3
... Logical Therapeutics, Inc., a,biotechnology company focused ... associated with poorly controlled inflammation, announced today,the ... controlled multi-dose,safety and pharmacokinetics study of LT-NS001, ... was conducted from December, 2007,through July, 2008 ...
... Pharmacology Space and Drug Target Knowledge Databases ... Related to Nuclear Receptors and Proteases, ... provider of,knowledge management solutions that accelerate life sciences discovery,announced ... The new offerings include knowledge databases for the important,drug ...
... Board: LFVN), the maker of Protandim(R), the only product,clinically ... announced,that the company,s President & CEO, David Brown, is ... The interview gives viewers an overview of the ... To view the clip in ...
Cached Biology Technology:Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug 2Aureus Pharma Releases New Unified Knowledge Database 2[video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.net's 3-Minute Press Show 2
(Date:8/27/2014)... trans-fats have largely succeeded in sidelining the use ... for its potential contributions to Americans, health conditions. ... the best way to assuage the nation,s insatiable ... Chemical & Engineering News (C&EN), the weekly ... In the article, Stephen Ritter, a senior correspondent ...
(Date:8/27/2014)... As of seven hours ago the Happy Camp Complex ... Northern California, the July complex had consumed 35,530 as ... seventeen fires on the Happy Camp Ranger District of ... the area on August 11, 2014. All but three ... following is a list of contained fires and their ...
(Date:8/26/2014)... St. Louis have developed algorithms to identify weak spots ... breaking. The technology, which needs to be refined before ... pinpoint minor strains and tiny injuries in the body,s ... is available online Aug. 27 in the Journal ... at the nexus of the physical and life sciences. ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3
... as being in perpetual conflict, but a new study by ... major research universities see religion and science as requiring distinct ... of life, ways of understanding reality, origins of Earth and ... science as being at odds and even in irreconcilable conflict," ...
... in German . Jean-Baptiste Lamarck would ... his belief that acquired traits can be passed on to ... of transformation went onto the ash heap of history. But ... can after all leave traces in the genomes of animals ...
... from the medical and research communities held high-level discussions ... Office of Naval Research (ONR), Sept. 16. "ONR,s ... with the Marine Corps component because of the physical ... Research Rear Adm. Nevin Carr. "This meeting of the ...
Cached Biology News:Science and religion do mix 2Science and religion do mix 3Epigenetic changes don't last 2Epigenetic changes don't last 3Epigenetic changes don't last 4ONR officials meet with Navy Surgeon General to coordinate medical research 2
... The Fluorescence Test Plate consists of an ... with Inert Organic Fluorescent Compounds embedded in ... used on BioTeks FLx800 and Synergy Multi-Detection ... for GLP compliance while reducing the need ...
... line is a Greenough stereomicroscope designed for the ... available with a choice of a large working ... (N2GG). This microscope can be easily connected to ... the same time giving you ultimate flexibility. Available ...
... MATra-si Reagent optimized for siRNA applications, contains ... with the nucleic acid of interest. Exploiting ... is then rapidly drawn towards and delivered ... transfection. MATra-si Reagent can be used for ...
...
Biology Products: